Marc Elia
Chairman bij INVIVYD, INC.
Vermogen: - $ op 29-02-2024
Profiel
Founder of Nivalis Therapeutics, Inc. and M28 Capital Management LP, Marc W.
Elia is Chairman at Invivyd, Inc. He is also on the board of SQZ Biotechnologies Co. and Fractyl Health, Inc.
He previously held the position of Partner at Bridger Capital LLC and Analyst at Bridger Management LLC.
He received an undergraduate degree from Carleton College.
Bekende belangen in openbare bedrijven
Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
---|---|---|---|---|
31-12-2023 | 0 ( -.--% ) | - $ | 29-02-2024 |
Actieve functies van Marc Elia
Bedrijven | Functie | Begin |
---|---|---|
SQZ BIOTECHNOLOGIES COMPANY | Director/Board Member | 09-08-2018 |
FRACTYL HEALTH, INC. | Director/Board Member | 16-06-2021 |
INVIVYD, INC. | Chairman | 01-07-2022 |
M28 Capital Management LP
M28 Capital Management LP Investment ManagersFinance M28 Capital Management LP (M28 Capital) is an independent, SEC-registered investment advisor and hedge fund manager headquartered in Stamford, Connecticut. The firm was founded by Marc Elia in 2019. M28 Capital provides investment advisory services on a discretionary basis to several private fund clients. | Founder | 01-09-2019 |
Eerdere bekende functies van Marc Elia
Bedrijven | Functie | Einde |
---|---|---|
Bridger Management LLC
Bridger Management LLC Investment ManagersFinance Bridger Management LLC (Bridger) is a registered investment advisor and hedge fund manager headquartered in New York City. The firm was founded by Roberto Mignone in 2000 and is a direct subsidiary of Bridger Management II LP. Bridger serves as the investment adviser, with discretionary trading authority, to private, pooled investment vehicles, the securities of which are offered through a private placement memorandum to accredited investors. | Analyst-Equity | 01-09-2019 |
Bridger Capital LLC | Corporate Officer/Principal | 01-09-2019 |
Adimab LLC
Adimab LLC BiotechnologyHealth Technology Adimab LLC provides human therapeutic antibodies. The firm has discovered antibodies for a wide variety of therapeutic targets within many disease areas, including oncology, immunomodulation, inflammation, neuroscience and pain, cardiovascular and metabolic disease and infectious disease. The company was founded in 2007 by Tillman Gerngross, Dane Wittrup and Errik Anderson and is headquartered in Lebanon, NH. | Director/Board Member | - |
Nivalis Therapeutics, Inc.
Nivalis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Nivalis Therapeutics, Inc. is a clinical stage pharmaceutical company, which engages in discovery, development, and commercialization of product for patients with cystic fibrosis. Its product includes N91115, a small molecule that addresses a defect in the cystic fibrosis transmembrane conductance regulator. The company was founded in 2008 and is headquartered in Boulder, CO. | Founder | - |
Opleiding van Marc Elia
Carleton College | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 3 |
---|---|
SQZ BIOTECHNOLOGIES COMPANY | Health Technology |
FRACTYL HEALTH, INC. | Commercial Services |
INVIVYD, INC. | Health Technology |
Bedrijven in privébezit | 5 |
---|---|
Bridger Management LLC
Bridger Management LLC Investment ManagersFinance Bridger Management LLC (Bridger) is a registered investment advisor and hedge fund manager headquartered in New York City. The firm was founded by Roberto Mignone in 2000 and is a direct subsidiary of Bridger Management II LP. Bridger serves as the investment adviser, with discretionary trading authority, to private, pooled investment vehicles, the securities of which are offered through a private placement memorandum to accredited investors. | Finance |
Adimab LLC
Adimab LLC BiotechnologyHealth Technology Adimab LLC provides human therapeutic antibodies. The firm has discovered antibodies for a wide variety of therapeutic targets within many disease areas, including oncology, immunomodulation, inflammation, neuroscience and pain, cardiovascular and metabolic disease and infectious disease. The company was founded in 2007 by Tillman Gerngross, Dane Wittrup and Errik Anderson and is headquartered in Lebanon, NH. | Health Technology |
Bridger Capital LLC | |
M28 Capital Management LP
M28 Capital Management LP Investment ManagersFinance M28 Capital Management LP (M28 Capital) is an independent, SEC-registered investment advisor and hedge fund manager headquartered in Stamford, Connecticut. The firm was founded by Marc Elia in 2019. M28 Capital provides investment advisory services on a discretionary basis to several private fund clients. | Finance |
Nivalis Therapeutics, Inc.
Nivalis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Nivalis Therapeutics, Inc. is a clinical stage pharmaceutical company, which engages in discovery, development, and commercialization of product for patients with cystic fibrosis. Its product includes N91115, a small molecule that addresses a defect in the cystic fibrosis transmembrane conductance regulator. The company was founded in 2008 and is headquartered in Boulder, CO. | Health Technology |